Gubra

Rapid weight loss can lead to muscle loss (sarcopenia), emphasizing the need for therapies that promote sustainable, muscle-preserving weight loss. Curious about how to benchmark your preclinical anti-obesity drug candidates for muscle-sparing effects? Explore our findings in the poster below and get in touch with us here: https://lnkd.in/daf3MB3f #ObesityResearch #MusclePreservation #ObesityDrugDevelopment #PreclinicalResearch

Choosing the right partner for #preclinical development is crucial for pharmaceutical and biotechnology companies. Gubra specializes in providing optimized, translational services that help streamline and accelerate your preclinical research. Let us help advance your science with our robust and reliable CRO services. Swipe through the carousel to discover why Gubra is the optimal choice for your preclinical needs and read more about our services here: https://lnkd.in/dUsHGtdD #PharmaceuticalResearch #Biotechnology #PreclinicalDevelopment #PreclinicalCRO

Gubra’s GAN DIO-MASH mouse model is an industry-leading, translational mouse model of liver biopsy-confirmed #MASH. We have rigorously validated the model using a series of clinically relevant anti-MASH drugs, including the glucagon-like peptide-1 (GLP-1) analogue semaglutide. Semaglutide has recently been reported to promote resolution of MASH and improve fibrosis stage in a recent pivotal clinical phase 3 trial in MASH patients (ESSENCE). Our studies indicate that histological outcomes of long-term semaglutide treatment in GAN DIO-MASH mice are comparable to corresponding topline results reported from the ESSENCE trial. Download the poster below and head to our website to learn more: https://lnkd.in/d_J4qN_E #TranslationalResearch #PreclinicalResearch #LiverHealth

Season's greetings from the entire team at Gubra! During this festive season, we extend our heartfelt thanks for your trust and collaboration. We are proud to support your preclinical research needs and look forward to achieving new milestones together in the year ahead. May your holidays be filled with joy, and may the New Year bring new opportunities and success. #TeamGubra #MilestonesAhead #PreclinicalResearch

We are happy to announce that, in close collaboration with Terns Pharmaceuticals, we have generated and validated a new humanized GLP-1 receptor mouse model, in which the endogenous murine GLP-1 receptor has been replaced by the human receptor at the whole-body level. This model is now available at Gubra for all our clients and will provide a physiologically relevant and translational platform to investigate in vivo efficacy, potency, and downstream signaling pathways of small-molecule GLP-1 receptor agonists. The easy accessibility of the model, as lean or obese (DIO), combined with Gubra's extensive expertise and capabilities in #obesity and metabolic diseases, will provide an excellent preclinical tool for anyone who wants to test a wide range of non-peptide GLP-1R agonists and translate their preclinical pharmacodynamics to the clinic. Check out our website or download the poster to learn more: https://lnkd.in/eCC4bcE3 #ObesityResearch #MetabolicResearch #NewMouseModel #PreclinicalResearch

Join Gubra as an Investor Relations & Strategy Officer — where your scientific expertise meets strategic innovation

Gubra's tailored kidney study protocols are designed to deliver optimized results with rapid start times. Are you seeking the latest insights into CKD, DKD, or AKI research? Curious about our standard kidney study outlines? Explore our newest research, presented at Kidney Week 2024, here: https://lnkd.in/e8uV4Q4N #KidneyResearch #KidneyDiseaseModels #RenalHealth #PreclinicalResearch

In collaboration with Intercept Pharmaceuticals, Nordic Bioscience, and research centers at The University of Edinburgh, we are excited to share our latest publication in Hepatology Communications. In this study, we explore anti-fibrotic mechanisms of action in liver for the dual FXR-TGR5 agonist, INT-767.   We’re glad that our biopsy-confirmed ob/ob-MASH mouse model is continuing to play a critical role in demonstrating the hepatoprotective effects against fibrosing #MASH and that our model provided robust preclinical data for INT-767. Read the full publication bellow.

Watch our Senior Scientist, Yasir Gallero-Salas, delivering an engaging presentation on the PFF mouse model of Parkinson’s disease - a collaborative research project with Frederikke Lynge Sørensen. The study garnered significant attention, and you can now dive deeper into the details in an interview with BioTechniques here: https://lnkd.in/esVuwgjW The progressive spreading of α-synuclein, along with alterations in the dopaminergic system, are key histopathological features of Parkinson’s disease. To learn more, explore our research in depth and download the poster here: https://lnkd.in/dN8fb9dD #ParkinsonsResearch #Neuroscience #SFN2024

Understanding how we commute to and from work is key to promoting sustainable transportation. That’s why we measure our commuting habits twice a year. On average, we commute 27 km each way, each working day. According to our latest surveys, 25% of us bike during the summer, and an impressive 19% brave the cold to continue biking in winter! Just last week, 16 of our dedicated Gubbies collectively covered 1708 km as part of the Danish Cyclists' Federation winter biking campaign. Sustainable commuting matters - not just for the environment but for our health and community spirit. Have a look at how Gubra supports green commuting here: https://lnkd.in/ekAccpyT How does your company encourage sustainable transport? Let us know in the comments below! #VCTA2024 #GreenTransport #SustainableCommuting